Notice of extraordinary general meeting
Filed with HKEX · Stock code 2696 · · 2 pages · English
Summary by 6ix AI
This filing is a notice for an extraordinary general meeting of Shanghai Henlius Biotech, Inc. The meeting will address several ordinary resolutions, including the revision of an annual cap for collaboration arrangements and the appointment of new directors. Shareholders are informed about the procedures for attending and voting at the meeting.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Shanghai Henlius Biotech, Inc. on 6ix
Earlier from Shanghai Henlius Biotech
- (1) Continuing connected transaction revision of annual cap for the collaboration arrangements under the HLX01 agreement (2) proposed appointment of non-executive director and independent non-executive director and notice of extraordinary general meeting
- Continuing connected transaction - revision of annual cap for the collaboration arrangements under the HLX01 agreement
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- List of directors and their roles and functions
- (1) Changes in non-executive director and independent non-executive director (2) appointment of chairman of the board and changes in composition of the board committees
Later from Shanghai Henlius Biotech
- Proxy form for the 2026 first extraordinary general meeting to be held on Monday, 23 November 2026 (or any adjournment thereof)
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement - the phase 1 clinical trial of HLX109 injection (a monoclonal antibody targeting IL1RAP) for the treatment of generalized pustular psoriasis has been approved to commence in australia
Follow Shanghai Henlius Biotech into a list and get an email when it puts out news.
Follow Shanghai Henlius Biotech